Topical Steroids
| TOPICAL STEROIDS | ||
|---|---|---|
|
Classification of topical steroid preparations by potency |
||
| LOW POTENCY | ||
|
Alclometasone dipropionate 0.05%
Fluocinolone acetonide 0.01%
Hydrocortisone base or acetate 1%
|
Hydrocortisone base or acetate 1% (continued)
Hydrocortisone base or acetate 1.85%
Hydrocortisone base or acetate 2%
|
Hydrocortisone base or acetate 2.5%
|
| INTERMEDIATE POTENCY | ||
|
Betamethasone dipropionate 0.05%†
Betamethasone valerate 0.12%
Clocortolone pivalate 0.1%
Desonide 0.05%
Desoximetasone 0.05%
Fluocinolone acetonide 0.01%
|
Fluocinolone acetonide 0.025%
Flurandrenolide 0.025%
Flurandrenolide 0.05%
Fluticasone propionate 0.005%
Fluticasone propionate 0.05%
Hydrocortisone probutate 0.1%
|
Hydrocortisone butyrate 0.1%
Hydrocortisone valerate 0.2%
Mometasone furoate 0.1%
Prednicarbate 0.1%
Triamcinolone acetonide 0.05%
Triamcinolone acetonide 0.1%Δ
Triamcinolone acetonide 0.2%
|
| HIGH POTENCY | ||
|
Betamethasone dipropionate, augmented 0.05%
Desoximetasone 0.05%
|
Desoximetasone 0.25%
Diflorasone diacetate 0.05%
Fluocinonide 0.05%
|
Halcinonide 0.1%‡
Triamcinolone acetonide 0.5%†
|
| SUPER HIGH POTENCY | ||
|
Betamethasone dipropionate, augmented 0.05%
|
Clobetasol propionate 0.05%
|
Fluocinonide 0.1%
Flurandrenolide 4mcg/sq cm
Halobetasol propionate 0.05%
|
| NOTES | ||
|
*Indicates that the product has more than one active ingredient. †Also available as a cream generically. ‡Also available as an emollient cream generically. ΔAlso available as a cream or ointment generically. ◊Also available as a cream, ointment, or lotion generically. The classification is based on vasoconstrictor assays and clinical studies. Potency varies according to the corticosteroid, its concentration, and the vehicle. In general, corticosteroids in lotions, creams, gels, andointments are increasingly more potent due to increased absorption from these vehicles. Absorption is increased by prolonged therapy, large areas of skin damage, and the use of occlusive dressings which may cause an increase in the incidence of side effects. (Rev. 1/2013) |
||
